Riskpilot← Back to searchSign inGet full accessIRL1117 AB
ABActiveOrg 5594484049Arvid Wallgrens Backe 20Economic activity was not specified by tax authority · NACE 0000Est. 20230 employees
Revenue 2024
SEK 0
EBITDA margin
—
+2% vs 2023
Equity ratio
8.2%
Financial strength
Net profit 2024
SEK -9,1M
+3% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -9,2M | +2% |
| Net profit | SEK -9,1M | +3% |
| Total assets | SEK 769K | -68% |
| Equity | SEK 63K | -63% |
| Employees | 0 | — |
Legal name
IRL1117 AB
Org number
5594484049
Legal form
Aktiebolag
NACE code
0000 · Economic activity was not specified by tax authority
Founded
14 september 2023
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska på kommersiella grunder bedriva forskning och utveckling av nya läkemedel, för behandling av neurologiska och psykiatriska sjukdomstillstånd, med huvudsaklig verkan på det centrala nervsystemets funktioner samt äga fast egendom, förvalta och utveckla immateriella rättigheter och bedriva därmed förenlig verksamhet.
Address
Arvid Wallgrens Backe 20
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2023 | 2024 |
|---|---|---|
| Revenue | 0 | 0 |
| Staff expenses | — | — |
| EBITDA | −9 381 | −9 166 |
| Depreciation & amort. | −0 | −0 |
| EBIT | −9 381 | −9 166 |
| Net financials | — | 20 |
| Profit before tax | −9 381 | −9 146 |
| Tax | −0 | −0 |
| Net profit | −9 381 | −9 146 |
| Item | 2023 | 2024 |
|---|---|---|
| Total assets | 2 395 | 769 |
| Equity | 169 | 63 |
| Long-term debt | 0 | 0 |
| Short-term debt | 2 226 | 706 |
| Total debt | 2 226 | 706 |
EBITDA margin
-916600000.0%
This company
15.8%
Market median
-5801265923% vs market
20232024
Equity ratio
8.2%
This company
38.2%
Market median
-79% vs market
20232024
Return on equity
-14517.5%
This company
18.4%
Market median
-78999% vs market
20232024
Net profit margin
-914600000.0%
This company
8.1%
Market median
-11291358125% vs market
20232024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20232024
Debt / equity
11.21×
This company
0.62×
Market median
-1708% vs market
20232024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-09-01 – 2023-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SU Chief Auditor | Chief Auditor | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2023 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2025 | — | — | |
| Deputy Board Member | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Integrative Research Laboratories Sweden AB | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
IRLAB Therapeutics AB
IRL1117 AB Board members of IRL1117 AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sofia Ulrika Ramsvik | Chief Auditor | 0 companies |
| Jan Anders Fredrik Lovén | Deputy Board Member | 0 companies |
| Jan Totte Dahlin | Deputy Board Member | 0 companies |
| Viktor Elias Bergman Gullmark | Deputy Board Member | 0 companies |
| Emma Maria Birgitta Wik | Deputy Board Member | 0 companies |
| Erik Viktor Siewertz | Deputy Board Member | 0 companies |
| Andreas Hans Eddie Ottosson | Deputy Board Member | 0 companies |
| Gunnar Olof Olsson | Chairman | 0 companies |
| Lars Anders Larsson | Board of Directors | 0 companies |
| Linn Mikaela Engman | Deputy Board Member | 0 companies |
| Emelie Sofia Bergh | Deputy Board Member | 0 companies |
| Aline Madeleine Pettersson | Deputy Board Member | 0 companies |
| Anna Carolina Maria Bjarnhagen | Deputy Board Member | 0 companies |
| Elin Anna Margareta Spjut | Deputy Board Member | 0 companies |
| Olina Kristina Maria Wåhlstedt | Deputy Board Member | 0 companies |
| Julia Engla Eva M Arnfridsdotter | Deputy Board Member | 0 companies |
| Ross Nicholas Waters | Board of Directors | 0 companies |
| Anna Kristina Torfgård | Chairman | 0 companies |
| Anna Klara Alina Bruksås Nybjörk | Deputy Board Member | 0 companies |